Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors

Mark Merchant(Revolution Medicines (United States)), Melissa R. Junttila(Unknown)
PLoS ONE
October 5, 2017
Cited by 92


Related Papers

Disruption of IRE1α through its kinase domain attenuates multiple myeloma
|Proceedings of the National Academy of Sciences|2019|115